

RTP Live from Chicago: Investigator Perspectives on Available Research Findings and Challenging Questions in the Management of Renal Cell Carcinoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III STELLAR-304 trial is currently evaluating the combination of zanzalintinib and nivolumab in which of the following settings?
 - a. Adjuvant therapy for clear cell renal cell carcinoma (RCC)
 - b. First-line therapy for advanced non-clear cell RCC
 - c. Second-line therapy after prior immunotherapy for advanced clear cell RCC
 - d. Heavily pretreated non-clear cell RCC for patients with no acceptable alternative options
2. In the Phase III COSMIC-313 trial evaluating the addition of cabozantinib to first-line nivolumab/ipilimumab, progression-free survival (PFS) was greatest in which of the following patient subgroups?
 - a. Intent to treat
 - b. IMDC poor risk
 - c. IMDC intermediate risk
3. Which of the following descriptions best reflects outcomes from the Phase III CheckMate 9ER trial evaluating nivolumab and cabozantinib versus sunitinib for previously untreated advanced RCC?
 - a. Improved PFS with nivolumab and cabozantinib
 - b. Improved PFS and overall survival with nivolumab and cabozantinib
 - c. No improvement with nivolumab and cabozantinib
4. Which of the following any-grade adverse events is most commonly associated with zanzalintinib for the management of RCC?
 - a. Headache
 - b. Hand-foot syndrome
 - c. Dry eye
 - d. Diarrhea
5. The ongoing Phase III STRIKE trial is evaluating pembrolizumab in combination with which of the following agents for the management of high-risk RCC?
 - a. Cabozantinib
 - b. Lenvatinib
 - c. Tivozanib
 - d. Belzutifan